ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs *

Roden DM . Drug-induced prolongation of the QT interval. N Engl J Med. 2005;350:1013–1022.

Yap YG Camm AJ . Drug induced QT prolongation and torsades de pointes. Heart 2003;89: 1363–1372.

Darpo B . Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes. Eur Heart J. 2001;3(suppl K):K70–K80.

Shah RR . Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol. 2002;16:147–156.

Shah RR . Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol. 2002;16:119–124.

Pratt CM Ruberg M Morganroth J Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J. 1996;131: 472–480.

Honig PK Wortham DC Zamani K Conner DP Mullin JC Cantilena LR . Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA. 1993; 269: 1513–1518.

Yang P Kanki H Drolet B Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943–1948.

Sanguinetti MC Jiang C Curran ME Keating MT . A -mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes he I_kr potassium channel. Cell. 1995;81:299–307.

Weissenburger J Nesterenko VV Antzelevitch D Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions with the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol. 2000;11: 115–164.

Antzelevitch C Belardinelli L Wu L Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent [in process citation]. J Cardiovasc Pharmacol Ther. 2004;9(suppl 1):S65–S83.

Antzelevitch C Belardinelli L Zygmunt AC Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904–910.

Wu L Shryock JC Song Y Li Y Antzelevitch C Belardinelli L . Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004;310:599–605.

Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. December 17, 1997. Available at: http://www.emea.eu.int/pdfs/human/swp/098696en.pdf. Accessed July 15, 2005.

International Conference on Harmonisation. E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (step 4). Available at: http://www.ich.org/cache/compo/276-254-1.html. Accessed July 15, 2005.

International Conference on Harmonisation. S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Available at: http://www.ich.org/cache/compo/276–254-1.html.

Demolis JL Kubitza D Tennezé L Funck-Brentano C . Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000;68:658–666.

Kivisto KT Lilja JJ Backman JT Neuvonen PJ . Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther. 1999;66:448–453.

van Haarst AD van't Klooster GAE van Gerven JMA The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther. 1998;64:542–546.

Demolis JL Charransol A Funck-Brentano C Jaillon P . Effects of a single oral dose of spar-floxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol. 1996;41: 499–503.

Noel GJ Natarajan J Chien S Hunt TL Goodman DB Abels R . Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73:292–303.

Agin MA Kazierad DJ Blum RA Assessing QT variability in healthy volunteers. Unpublished manuscript.

Dota C Skallefell B Edvardsson N Fager G . Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction. Ann Noninvasive Electrocardiol. 2002;7: 289–301.

Patterson S Agin M Anziano R Investigating drug-induced QT and QTc Prolongation in the clinic: a review of statistical design and analysis considerations. Report from Pharmaceutical Research and Manufacturer of America QT statistics expert team. Drug Inf J. 2005. In press.

Malik M Camm AJ . Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 2001; 24: 323–351.